

Office No. 106, Sheraton Classic, Dr. Charta Singh Colony, J.B Nagar, Andheri East, Mumbai 400092, Maharashtra, India

Phone: +91 9653484516 Email: <u>urvashi@umco.co.in</u> Website: <u>www.umco.co.in</u>

Independent Auditor's Report on the Quarterly and Year to Date Audited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors of Kopran Lifesciences Limited

## Report on the Audit of the Standalone Financial Result Opinion

We have audited the accompanying Statement of standalone financial results of Kopran Lifesciences Limited ("the Company") for the quarter and year ended 31 March 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended 31 March 2025:

- (i) is presented in accordance with the requirements of Regulations 33 of the Listing Regulations; and
- (ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net loss and total comprehensive income and other financial information of the Company for the quarter and year then ended 31 March 2025.

## **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the standalone financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

## Management's Responsibilities for the Standalone Financial Results

This Statement of standalone financial results has been prepared on the basis of standalone financial statements.

# Urvashí Maharshí & Co.

## Chartered Accountants

## INDEPENDENT AUDITOR'S REPORT (CONTINUED)

## **Kopran Lifesciences Limited**

The Company's Board of Directors are responsible for the preparation and presentation of these standalone financial results that give a true and fair view of the net loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

## Auditor's responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for *our* opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

# Urvashí Maharshí & Co.

## Chartered Accountants

#### INDEPENDENT AUDITOR'S REPORT (CONTINUED)

## **Kopran Lifesciences Limited**

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulations 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Standalone Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Results, including the disclosures, and whether the Standalone Financial Results represents the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the Company to express an opinion on the standalone financial results.

Materiality is the magnitude of misstatements in the Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors (i) in planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

# Urvashí Maharshí & Co.

## Chartered Accountants

## INDEPENDENT AUDITOR'S REPORT (CONTINUED)

## **Kopran Lifesciences Limited**

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **Other Matters**

The standalone financial results include the results for the quarter ended 31 March 2025 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us, as required under the Listing Regulations. Our opinion on the standalone financial results is not modified in respect of this matter.

#### For URVASHI MAHARSHI & CO.

Chartered Accountants Firm's Registration No. 152552W

URVASHI Digitally signed by URVASHI DILIP MAHARSHI

MAHARSHI Date: 2025.05.14
18:50:32 +05'30'

Urvashi D. Maharshi


Proprietor

Membership No. 197107

Date: 14 May 2025 Place: Mumbai

UDIN No.: 25197107BMIAJY6341





## KOPRAN (H.K.) LIMITED YEAR ENDED 31ST MARCH, 2025 DIRECTORS' REPORT

The directors presents their annual report and the audited financial statements for the year ended 31st March, 2025.

## PRINCIPAL ACTIVITIES

During the year, the principal activities of the company was engaged in trading of medical equipments and chemical reagents. There was no significant change of principal activity during the year.

#### RESULTS AND STATE OF AFFAIRS

The results of the Company for the year ended 31 March, 2025 and the state of the Company's affairs at that date are set out in the Company's separate financial statements on pages 6 to 7 respectively.

#### SHARE CAPITAL AND RESERVES

The movements in capital and reserves during the year are set out in Note 3 to the separate financial statements. The Company has not issued any debentures during the year.

## **EQUITY-LINKED AGREEMENTS**

The Company has not entered into an equity-linked agreement during the financial year.

## PERMITTED INDEMNITY PROVISION

The Company has not made any permitted indemnity provision for the benefit of any director of the Company, or of its associate Company during the year.

## MANAGEMENT CONTRACTS

The Company did not enter into any contract, other than the contracts of service with the sole director or any person engaged in the full-time employment, whereby any individual, firm or body corporate undertakes the management and administration of the whole, or any substantial part of any business of the Company.

## DIVIDEND

The directors do not recommend any payment of dividend in respect of the year ended 31st March, 2025 (2024: HK\$Nil).

#### **DIRECTORS' INTEREST IN CONTRACTS**

No contract of significance to which the Company, was a party and in which a director of the Company had a material interest, whether directly or indirectly, subsisted at the end of the year or at any time during the year.

#### ARRANGEMENT TO ACQUIRE SHARES OR DEBENTURES

At no time during the year was the Company or its subsidiary a party to any arrangement to enable the sole director of the Company to acquire benefits by means of acquisition of shares in or debentures of the Company or any other body corporate.

## **DIRECTORS**

The directors of the Company during the year and up to the date of this report was:

Rajesh Kumar

Chandramohan Balkishan SINGHI

Venkata Kamesh BHAMIDIPATI

There being no provision in the Company's Articles of Association for retirement by rotation, the sole director continues in office.

#### **BUSINESS REVIEW**

The Company falls within reporting exemption for the financial year. Accordingly, the Company is exempted from preparing a business review.

## **AUDITOR**

The accounts have been audited by Messrs. Simon Chong & Company, Certified Public Accountants, who retire and being eligible offer themselves for reappointment.

On behalf of the Board

Director:

Hong Kong, 26th May, 2025

## SIMON CHONG & COMPANY

Certified Public Accountants (Practising)

SOLE PRACTITIONER: SIMON CHONG F.C.C.A., F.C.P.A.(Practising)

, ,

ROOM 1426, 14/FL., HOLLYWOOD PLAZA, 610 NATHAN ROAD, MONGKOK, KOWLOON

Tel No.: 2388 9038 Fax No.: 2388 9903

E-MAIL: simonco@simonchonghk.com

電 話:二三八八九九〇三八荷李活商業中心十四字樓一四二六室荷李活商業中心十四字樓一四二六室

## INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF

## KOPRAN (H.K.) LIMITED

(incorporated in Hong Kong with limited liability)

#### Opinion

We have audited the financial statements of KOPRAN (H.K.) LIMITED ("the Company") set out on pages 6 to 9, which comprise the statement of financial position as at 31st March, 2025, and the income statement for the year ended 31st March, 2025, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the financial statements of the Company are prepared, in all material respects, in accordance with the Hong Kong Small and Medium-sized Entity Financial Reporting Standard ("SME-FRS") issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") and have been properly prepared in compliance with the Hong Kong Companies Ordinance.

#### **Basis for Opinion**

We conducted our audit in accordance with Hong Kong Standards on Auditing ("HKSAs") and with reference to Practice Note 900 (Revised), Audit of Financial Statements Prepared in Accordance with the SME-FRS issued by the HKICPA. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the HKICPA's Code of Ethics for Professional Accountants ("the Code"), and we have fulfilled our other responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## Other Information

The directors are responsible for the other information. The other information comprises the information included in annual report, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

## SIMON CHONG & COMPANY

Certified Public Accountants (Practising)

**SOLE PRACTITIONER:** 

SIMON CHONG F.C.C.A., F.C.P.A.(Practising)

ROOM 1426, 14/FL., HOLLYWOOD PLAZA, 610 NATHAN ROAD, MONGKOK, KOWLOON

Tel No.: 2388 9038 Fax No.: 2388 9903

E-MAIL: simonco@simonchonghk.com

## Responsibilities of the Directors for the Financial Statements

The directors are responsible for the preparation of the financial statements in accordance with the SME-FRS issued by the HKICPA and the Hong Kong Companies Ordinance, and for such internal control as the directors determine are necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

## Auditor's Responsibilities for the Audit of the Financial Statements

It is our responsibility to form an independent opinion, based on our audit, on those financial statements and to report our opinion solely to you, as a body, in accordance with section 405 of the Hong Kong Companies Ordinance and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with HKSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with HKSAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.

## SEMON CHONG & COMPANY

Certified Public Accountants (Practising)

**SOLE PRACTITIONER:** 

SHON CHONG F.C.C.A., F.C.P.A.(Practising)

EDOM 1426, 14/FL., HOLLYWOOD PLAZA, C10 NATHAN ROAD, MONGKOK, KOWLOON

Tel No.: 2388 9038 Fax No.: 2388 9903

EMAIL: simonco@simonchonghk.com

圖文傳真:二三八八九九○三本 話:二三八八九○三八 前率活商業中心十四字樓一四二六室 がま は 六一○ 號 上 錫 乾 會計 師事務所

## Auditor's Responsibilities for the Audit of the Financial Statements (Continued)

Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Simon Chong & Company Certified Public Accountants (Practising)

Hong Kong, 26th May, 2025

Practising Certificate number: P02100

SC/208-25

## KOPRAN (H.K.) LIMITED STATEMENT OF FINANCIAL POSITION AS AT 31ST MARCH, 2025

(Expressed in Hong Kong dollars)

ASSETS		31/03/2025	31/03/2024		
NON-CURRENT ASSETS Property, plant & equipments - Note 4		32,200.57	40,250.69		
CURRENT ASSETS  Utility deposits  Trade debtors  Cash at banks & in hand	19,700.00 2,007,227.14 153,165.21 2,180,092.35		19,700.00 2,008,478.45 192,233.73 2,220,412.18		
CURRENT LIABILITIES Accrued expenses NET CURRENT ASSETS	4,000.00	2,176,092.35	48,637.52 48,637.52 2,171,774.66		
NET ASSETS	-	2,208,292.92	2,212,025.35		
EQUITY Share capital - Note 3 Accumulated loss TOTAL EQUITY	- -	2,318,750.00 (110,457.08) 2,208,292.92	2,318,750.00 (106,724.65) 2,212,025.35		
Approved by the board of directors on 26th May, 2025 and signed on its behalf by					

Report for mo

Director'

Director

The accompanying Accounting Policies and Explanatory Notes form an integral part of, and should be read in conjunction with these financial statements.

## KOPRAN (H.K.) LIMITED

## STATEMENT OF COMPREHENSIVE INCOME

## FOR THE YEAR ENDED 31ST MARCH, 2025

(Expressed in Hong Kong dollars)

Sales		Year ended 31/03/2025 1,107,015.21	Year ended 31/03/2024 55,562.65
Less: Cost of Sales Purchases Gross profit		1,087,800.00 19,215.21	45,637.52 9,925.13
Less: General & Administrative Expenses			
Auditors' remuneration	4,000.00		3,000.00
Bank Charges	4,747.52		4,574.38
Business registration fee	2,200.00		2,150.00
Depreciation	8,050.12		10,062.67
Professional fees	3,950.00		4,005.00
Net loss for the year		22,947.64 (3,732.43)	23,792.05 (13,866.92)
Accumulated loss brought forward  Retained profit/(Accumulated loss) carried forward		(106,724.65) (110,457.08)	(92,857.73) (106,724.65)

# KOPRAN (H.K.) LIMITED ACCOUNTING POLICIES AND EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2025

## 1. Reporting Entity

KOPRAN (H.K.) LIMITED is a company incorporated in Hong Kong with limited liability.

The registered office is located at Room 328, Peninsula Centre, 67 Mody Road, Tsim Sha Tsui East, Kowloon.

During the year, the principal activity of the company was engaged in trading of medical equipments and chemical reagents.

## 2. Significant Accounting Policies

The company qualifies for the reporting exemption as a small private company under section 359(1)(a) of the Hong Kong Companies Ordinance (Cap. 622) and is therefore entitled to prepare and present its financial statements in accordance with the Small and Medium-sized Entity Financial Reporting Standard (SME-FRS) issued by the Hong Kong Institute of Certified Public Accountants.

These financial statements comply with the SME-FRS and have been prepared under the accrual basis of accounting and on the basis that the company is a going concern.

The measurement base adopted is the historical cost, accrual and going concern basis.

(a) Property, Plant and Equipment

Depreciation of fixed assets

Depreciation is calculated to write off the cost of fixed assets over their estimated useful lives on a reducing balance method, at the following rates per annum.

Furniture & fixtures

20%

Medical equipments

20%

(b) Foreign Currencies

Transactions arising in foreign currencies during the year are converted at exchange rates ruling at the transaction dates. Monetary balances in foreign currency at the year end are translated at rates of exchange ruling at the balance sheet date. All exchange differences are dealt with in the profit and loss account.

## (c) Taxation

Income tax expense represents current tax expense. The income tax payable represents the amounts expected to be paid to the taxation authority, using the tax rates (and tax laws) that have been enacted or substantively enacted by the balance sheet date.

## 3. Share Capital

31/03/2025

31/03/2024

Issued and fully paid up: 2,318,750 ordinary shares

HK\$2,318,750.00

HK\$2,318,750

During the year under review, there was no change in the share capital.

# KOPRAN (H.K.) LIMITED \*\*ACCOUNTING POLICIES AND EXPLANATORY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH, 2025

## 4. Property, plant & equipments

220,000,0000000000000000000000000000000	Furniture & fixtures	Medical equipments	
Cost			
Balance brought forward	174,905.30	468,579.84	643,485.14
Addition during the year	0.00	0.00	0.00
At 31/03/2025	174,905.30	468,579.84	643,485.14
Accumulated Depreciation			
Balance brought forward	174,905.30	428,329.15	603,234.45
Charge for the year	0.00	8,050.12	8,050.12
At 31/03/2025	174,905.30	436,379.27	611,284.57
Net Book Value			
At 31/03/2025	0.00	32,200.57	32,200.57
At 31/03/2024	0.00	40,250.69	40,250.69

## 5. Change in Equity

	Share	Retained	
	capital	earnings	Total
Balance as at 31/03/2024	2,318,750.00	(106,724.65)	2,212,025.35
(Loss) for the year	0.00	(3,732.43)	(3,732.43)
Balance as at 31/03/2025	2,318,750.00	(110,457.08)	2,208,292.92

## 6. Remuneration of Directors

No fees or other emoluments was paid or payable to any directors for services rendered during the year. (2024: Nil)

## 7. Ultimate Holding Company

The directors of the company consider Kopran Limited, a company incorporated in India, is its ultimate holding company.

## 8. Taxation

No provision for profit tax is made in the accounts as the allowable losses brought forward exceed the estimated assessable profits for the year.

## 9. Approval of financial statements

These financial statements were authorised for issue by the company's Board of Directors on 26th May, 2025.